we have heard repeatedly about LymPro being the "Gold Standard" for at least the last 12 months - and longer

then we have a well noted and well respected biotech analyst drop his LymPro revenue projections quite literally overnight - all the way down to the basement level for the next 2 years: $1-Mil. & $3.5-Mil. respectively - out of a well noted $150-Mil. RUO market

then the CEO holds a 1-day notice CC for the sole purpose of disseminating company info, material events and updating the shareholder community as to the company's progress - yet all we heard was that LymPro remains on track

either Gerald is a very good dancer or he doesn't know Wall Street psychology and how to speak to it....

or LymPro just went from Gold to dust and is now critically flawed

I simply can't wrap my mind around the possibility of the later when there has been testing labs such as Beckdin Dickinson and ICON who have continuously validated LymPro's specificity and sensitivity numbers consistently within the last 18 months

so which one is it?

either Jason Napadano is completely wrong and suffering from acute early stage Alzheimers....

or ICON has stumbled upon a late stage fly in the LymPro ointment